Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis
The cardiovascular and kidney benefits of finerenone were not modified by an acute eGFR change after drug initiation.
Authors
- Stefan D. Anker (ORCID: https://orcid.org/0000-0002-0805-8683)
- Luke Roberts (ORCID: https://orcid.org/0000-0002-9910-4648)
- Gerasimos S Filippatos (ORCID: https://orcid.org/0000-0002-5640-0332)
- Pantelis Sarafidis (ORCID: https://orcid.org/0000-0002-9174-4018)
- Luís M. Ruilope (ORCID: https://orcid.org/0000-0001-6278-7951)
- Bertram Pitt (ORCID: https://orcid.org/0000-0001-5880-275X)
- Meike Brinker (ORCID: https://orcid.org/0000-0002-1560-9535)
- Charlie Scott (ORCID: https://orcid.org/0000-0002-2816-4889)
- Andrea Lage
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
- Sankar Dass Navaneethan (ORCID: https://orcid.org/0000-0002-4953-7795)
- Phyllis August
Institutions
- Steno Diabetes Centers (DK)
- Baylor College of Medicine (US)
- National and Kapodistrian University of Athens (GR)
- Cornell University (US)
- Aristotle University of Thessaloniki (GR)
- University of Michigan (US)
- Research Institute Hospital 12 de Octubre (ES)
- Hellenic Agency for Local Development and Local Government (GR)
- German Centre for Cardiovascular Research (DE)
- Bayer (United Kingdom) (GB)
- Bayer (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- Kidney International
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1016/j.kint.2025.03.018
- Citations
- 11
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 14.24
Funders
- Bayer
- University of Pittsburgh